Drug Trial Radar · NCT07198087
A Study to Investigate the Pharmacokinetics of Tirabrutinib in Participants With Mild, Moderate, and Severe Hepatic Impairment Compared to Healthy Participants
Last checked: Nov 20, 2026Latest source record: Jun 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
40
Actual
Start
Oct 1, 2025
Primary completion
Apr 9, 2026
Study completion Apr 20, 2026
Sponsor
- Lead sponsor
- Ono Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Sep 30, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Other
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
A study to investigate the pharmacokinetics of tirabrutinib in participants with mild, moderate, and severe hepatic impairment compared to healthy participants
Conditions
- Primary Central Nervous System Lymphoma (PCNSL)
Interventions
TirabrutinibDrug
Administered orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pharmacokinetic parameter of tirabrutinib: CmaxTime frame: 72 hour
- Pharmacokinetic parameter of tirabrutinib: TmaxTime frame: 72 hour
- Pharmacokinetic parameter of tirabrutinib: AUClastTime frame: 72 hour
- Pharmacokinetic parameter of tirabrutinib: AUCinfTime frame: 72 hour
- Pharmacokinetic parameter of tirabrutinib: T1/2Time frame: 72 hour
- Pharmacokinetic parameter of tirabrutinib: CL/FTime frame: 72 hour
- Pharmacokinetic parameter of tirabrutinib: Volume of distribution (Vd)Time frame: 72 hour
- Protein binding ratio of tirabrutinib in plasmaTime frame: 72 hour
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Arizona Liver Health
Chandler, Arizona
Panax Clinical Research
Miami Lakes, Florida
Orlando Clinical Research Center, Inc.
Orlando, Florida
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.